Bydureon BCise Approved for Adolescents

The Bydureon BCise once-weekly injection has received FDA approval for use in children and teens age 10-17 after trial results showed it significantly reduced blood sugar in adolescents. This is the first once-weekly dose of the GLP-1 receptor agonist drug class approved for older children. Read more

Posted in Type II Drugs